JAMA : the journal of the American Medical Association
-
Introducing new medical devices into routine practice raises concerns because patients and outcomes may differ from those in randomized trials. ⋯ Among patients undergoing TAVR in US clinical practice, at 1-year follow-up, overall mortality was 23.7%, the stroke rate was 4.1%, and the rate of the composite outcome of death and stroke was 26.0%. These findings should be helpful in discussions with patients undergoing TAVR.